BACKGROUND: Non-cardia gastric adenocarcinoma is positively associated with Helicobacter pylori infection and atrophic gastritis. The role of H pylori infection and atrophic gastritis in cardia cancer is unclear. AIM: To compare cardia versus non-cardia cancer with respect to the premorbid state of the stomach. METHODS: Nested case-control study. To each of 129 non-cardia and 44 cardia cancers, three controls were matched. Serum collected a median of 11.9 years before the diagnosis of cancer was tested for anti-H pylori antibodies, pepsinogen I:II and gastrin. RESULTS: Non-cardia cancer was positively associated with H pylori (OR 4.75, 95% CI 2.56 to 8.81) and gastric atrophy (pepsinogen I:II <2.5; OR 4.47, 95% CI 2.71 to 7.37). The diffuse and intestinal histological subtypes of non-cardia cancer were of similar proportions and both showed a positive association with H pylori and atrophy. Cardia cancer was negatively associated with H pylori (OR 0.27, 95% CI 0.12 to 0.59), but H pylori-positive cardia cancer showed an association with gastric atrophy (OR 3.33, 95% CI 1.06 to 10.5). The predominant histological subtype of cardia cancer was intestinal and was not associated with gastric atrophy compared with the diffuse subtype ((OR 0.72, 95% CI 0.19 to 2.79) vs (OR 3.46, 95% CI 0.32 to 37.5)). Cardia cancer in patients with atrophy had an intestinal: diffuse ratio (1:1) similar to non-cardia cancer (1.9:1), whereas cardia cancers in patients without atrophy were predominantly intestinal (7:1). CONCLUSION: These findings indicate two aetiologies of cardia cancer, one associated with H pylori atrophic gastritis, resembling non-cardia cancer, and the other associated with non-atrophic gastric mucosa, resembling oesophageal adenocarcinoma. Serological markers of gastric atrophy may provide the key to determining gastric versus oesophageal origin of cardia cancer.
BACKGROUND:Non-cardia gastric adenocarcinoma is positively associated with Helicobacter pylori infection and atrophic gastritis. The role of H pylori infection and atrophic gastritis in cardia cancer is unclear. AIM: To compare cardia versus non-cardia cancer with respect to the premorbid state of the stomach. METHODS: Nested case-control study. To each of 129 non-cardia and 44 cardia cancers, three controls were matched. Serum collected a median of 11.9 years before the diagnosis of cancer was tested for anti-H pylori antibodies, pepsinogen I:II and gastrin. RESULTS:Non-cardia cancer was positively associated with H pylori (OR 4.75, 95% CI 2.56 to 8.81) and gastric atrophy (pepsinogen I:II <2.5; OR 4.47, 95% CI 2.71 to 7.37). The diffuse and intestinal histological subtypes of non-cardia cancer were of similar proportions and both showed a positive association with H pylori and atrophy. Cardia cancer was negatively associated with H pylori (OR 0.27, 95% CI 0.12 to 0.59), but H pylori-positive cardia cancer showed an association with gastric atrophy (OR 3.33, 95% CI 1.06 to 10.5). The predominant histological subtype of cardia cancer was intestinal and was not associated with gastric atrophy compared with the diffuse subtype ((OR 0.72, 95% CI 0.19 to 2.79) vs (OR 3.46, 95% CI 0.32 to 37.5)). Cardia cancer in patients with atrophy had an intestinal: diffuse ratio (1:1) similar to non-cardia cancer (1.9:1), whereas cardia cancers in patients without atrophy were predominantly intestinal (7:1). CONCLUSION: These findings indicate two aetiologies of cardia cancer, one associated with H pylori atrophic gastritis, resembling non-cardia cancer, and the other associated with non-atrophic gastric mucosa, resembling oesophageal adenocarcinoma. Serological markers of gastric atrophy may provide the key to determining gastric versus oesophageal origin of cardia cancer.
Authors: James G Fox; Arlin B Rogers; Melanie Ihrig; Nancy S Taylor; Mark T Whary; Graham Dockray; Andrea Varro; Timothy C Wang Journal: Cancer Res Date: 2003-03-01 Impact factor: 12.701
Authors: H Väänänen; M Vauhkonen; T Helske; I Kääriäinen; M Rasmussen; H Tunturi-Hihnala; J Koskenpato; M Sotka; M Turunen; R Sandström; M Ristikankare; A Jussila; P Sipponen Journal: Eur J Gastroenterol Hepatol Date: 2003-08 Impact factor: 2.566
Authors: Weimin Ye; Maria Held; Jesper Lagergren; Lars Engstrand; William J Blot; Joseph K McLaughlin; Olof Nyrén Journal: J Natl Cancer Inst Date: 2004-03-03 Impact factor: 13.506
Authors: P Sipponen; P Ranta; T Helske; I Kääriäinen; T Mäki; A Linnala; O Suovaniemi; A Alanko; M Härkönen Journal: Scand J Gastroenterol Date: 2002-07 Impact factor: 2.423
Authors: Johan L Dikken; Cornelis J H van de Velde; Daniel G Coit; Manish A Shah; Marcel Verheij; Annemieke Cats Journal: Therap Adv Gastroenterol Date: 2012-01 Impact factor: 4.409
Authors: Tan Han Loong; Ngiu Chai Soon; Nik Ritza Kosai Nik Mahmud; Jeevinesh Naidu; Rafiz Abdul Rani; Nazefah Abdul Hamid; Marjanu Hikmah Elias; Isa Mohamed Rose; Azmi Tamil; Norfilza M Mokhtar; Raja Affendi Raja Ali Journal: Biomed Rep Date: 2017-09-20
Authors: Ramin Shakeri; Reza Malekzadeh; Dariush Nasrollahzadeh; Michael Pawlita; Michael Pawilta; Gwen Murphy; Farhad Islami; Masoud Sotoudeh; Angelika Michel; Arash Etemadi; Tim Waterboer; Hossein Poustchi; Paul Brennan; Paolo Boffetta; Sanford M Dawsey; Farin Kamangar; Christian C Abnet Journal: Cancer Res Date: 2015-09-17 Impact factor: 12.701
Authors: Hee-Won Kwak; Il Ju Choi; Chan Gyoo Kim; Jong Yeul Lee; Soo-Jeong Cho; Bang Wool Eom; Hong Man Yoon; Jungnam Joo; Keun Won Ryu; Young-Woo Kim Journal: World J Gastroenterol Date: 2015-04-21 Impact factor: 5.742